Payment overview · 2025
General Payments
$127.26
7 reported records · 4 companies
Healthcare provider profile · identity verified
Darian Ratliff, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HAZARD, KY · NPI 1760484216
Verified facts
What the public records show
CMS Open Payments records show Darian Ratliff, MD received $127.26 in general payments during 2025 across 7 reported records.
ABBVIE INC. accounted for 50.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Nurtec Odt.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 143 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 181 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $63.71 | 50.1% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $32.66 | 25.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $16.57 | 13.0% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $14.32 | 11.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $127.26 | 7 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $63.71 | 3 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $63.71 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $17.31 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $16.57 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.35 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $14.32 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 181 | exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
53 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
143 | 20 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
181 | 38 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 689 | 162 |
| Amlodipine Besylate | Amlodipine Besylate | 656 | 168 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 587 | 99 |
| Pantoprazole Sodium | Pantoprazole Sodium | 579 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 560 | 117 |
| Gabapentin | Gabapentin | 529 | 82 |
| Losartan Potassium | Losartan Potassium | 503 | 122 |
| Metoprolol Succinate | Metoprolol Succinate | 432 | 101 |
| Lisinopril | Lisinopril | 365 | 89 |
| Metoprolol Tartrate | Metoprolol Tartrate | 328 | 80 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 324 | 79 |
| Tramadol Hcl | Tramadol Hcl | 242 | 53 |
| Escitalopram Oxalate | Escitalopram Oxalate | 234 | 60 |
| Omeprazole | Omeprazole | 231 | 56 |
| Metformin Hcl | Metformin Hcl | 226 | 67 |
| Famotidine | Famotidine | 218 | 50 |
| Furosemide | Furosemide | 214 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 202 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 188 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 188 | 75 |
| Eliquis | Apixaban | 181 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 172 | 42 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 161 | 24 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 158 | 47 |
| Finasteride | Finasteride | 154 | 30 |
| Allopurinol | Allopurinol | 152 | 34 |
| Pravastatin Sodium | Pravastatin Sodium | 149 | 42 |
| Ozempic | Semaglutide | 143 | 20 |
| Alprazolam | Alprazolam | 141 | 26 |
| Potassium Chloride | Potassium Chloride | 140 | 43 |
| Hydralazine Hcl | Hydralazine Hcl | 136 | 39 |
| Amitriptyline Hcl | Amitriptyline Hcl | 132 | 29 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 132 | 42 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 120 | 37 |
| Ezetimibe | Ezetimibe | 117 | 29 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 117 | 29 |
| Atenolol | Atenolol | 112 | 26 |
| Farxiga | Dapagliflozin Propanediol | 108 | 28 |
| Sertraline Hcl | Sertraline Hcl | 108 | 28 |
| Simvastatin | Simvastatin | 105 | 26 |
| Meloxicam | Meloxicam | 101 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 100 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 97 | 28 |
| Vascepa | Icosapent Ethyl | 92 | 13 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 12 |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 87 | 13 |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 86 | 21 |
| Carvedilol | Carvedilol | 85 | 19 |
| Montelukast Sodium | Montelukast Sodium | 85 | 21 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 84 | 23 |
| Lorazepam | Lorazepam | 81 | 11 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 78 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 76 | 17 |
| Tizanidine Hcl | Tizanidine Hcl | 76 | 19 |
| Trazodone Hcl | Trazodone Hcl | 74 | 16 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 74 | 13 |
| Zolpidem Tartrate | Zolpidem Tartrate | 74 | 14 |
| Ibuprofen | Ibuprofen | 68 | 20 |
| Jardiance | Empagliflozin | 68 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 68 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 66 | 23 |
| Meclizine Hcl | Meclizine Hcl | 66 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 65 | 16 |
| Nifedipine Er | Nifedipine | 58 | 14 |
| Fluoxetine Hcl | Fluoxetine Hcl | 57 | suppressed |
| Glimepiride | Glimepiride | 57 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 57 | 21 |
| Mounjaro | Tirzepatide | 56 | suppressed |
| Synthroid | Levothyroxine Sodium | 53 | 11 |
| Buspirone Hcl | Buspirone Hcl | 52 | 15 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 52 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 50 | 18 |
| Fluconazole | Fluconazole | 50 | 30 |
| Paroxetine Hcl | Paroxetine Hcl | 49 | suppressed |
| Aripiprazole | Aripiprazole | 46 | 11 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 46 | suppressed |
| Glipizide | Glipizide | 46 | 15 |
| Celecoxib | Celecoxib | 45 | 11 |
| Colestipol Hcl | Colestipol Hcl | 45 | 12 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 45 | 21 |
| Tresiba Flextouch U-200 | Insulin Degludec | 45 | suppressed |
| Clonazepam | Clonazepam | 44 | suppressed |
| Lansoprazole | Lansoprazole | 44 | suppressed |
| Ramipril | Ramipril | 44 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 42 | 11 |
| Irbesartan | Irbesartan | 42 | 11 |
| Warfarin Sodium | Warfarin Sodium | 42 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 40 | suppressed |
| Repatha Sureclick | Evolocumab | 40 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 40 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 39 | suppressed |
| Linzess | Linaclotide | 39 | suppressed |
| Pregabalin | Pregabalin | 38 | suppressed |
| Trulicity | Dulaglutide | 38 | suppressed |
| Colchicine | Colchicine | 37 | suppressed |
| Novolog Flexpen | Insulin Aspart | 37 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 35 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | suppressed |
| Lactulose | Lactulose | 34 | 15 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 33 | 14 |
| Brilinta | Ticagrelor | 32 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 32 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 32 | 25 |
| Fenofibrate | Fenofibrate Nanocrystallized | 31 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 31 | 14 |
| Prednisone | Prednisone | 29 | suppressed |
| Spironolactone | Spironolactone | 29 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 28 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 28 | suppressed |
| Lovastatin | Lovastatin | 28 | suppressed |
| Nitroglycerin | Nitroglycerin | 28 | 15 |
| Soliqua 100-33 | Insulin Glargine/Lixisenatide | 28 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | suppressed |
| Temazepam | Temazepam | 27 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 26 | 11 |
| Clonidine Hcl | Clonidine Hcl | 25 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 25 | suppressed |
| Fentanyl | Fentanyl | 24 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Methocarbamol | Methocarbamol | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 22 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 22 | suppressed |
| Sucralfate | Sucralfate | 22 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 22 | 11 |
| Bumetanide | Bumetanide | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | 11 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 21 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 20 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 20 | suppressed |
| Clotrimazole | Clotrimazole | 19 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 18 | suppressed |
| Bupropion Xl | Bupropion Hcl | 18 | suppressed |
| Estradiol | Estradiol | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Jentadueto | Linagliptin/Metformin Hcl | 18 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 18 | suppressed |
| Acebutolol Hcl | Acebutolol Hcl | 17 | suppressed |
| Baclofen | Baclofen | 17 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 17 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Cefprozil | Cefprozil | 16 | 15 |
| Cilostazol | Cilostazol | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | 14 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 16 | suppressed |
| Repatha Pushtronex | Evolocumab | 15 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 14 | suppressed |
| Kerendia | Finerenone | 14 | suppressed |
| Naproxen | Naproxen | 14 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Levofloxacin | Levofloxacin | 13 | 13 |
| Memantine Hcl | Memantine Hcl | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 12 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 12 | suppressed |
| Dyrenium | Triamterene | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Levetiracetam | Levetiracetam | 12 | suppressed |
| Mirtazapine | Mirtazapine | 12 | suppressed |
| Valsartan | Valsartan | 12 | suppressed |
| Lamotrigine | Lamotrigine | 11 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 11 | suppressed |
| Nystatin | Nystatin | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $127.26 · 7 records | ABBVIE INC. | ABRYSVO, COMIRNATY, Cologuard Collection Kit, ELIQUIS, NURTEC ODT, PREVNAR 20, QULIPTA, UBRELVY, Wegovy | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error